Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy

被引:14
|
作者
Poole, Chris D. [1 ]
Bannister, Christian A. [1 ]
Andreasen, Jakob Norgaard [2 ]
Andersen, Jens Strodl [2 ]
Currie, Craig J. [1 ]
机构
[1] Cardiff Univ, Cochrane Inst Primary Care & Publ Hlth, Cardiff CF10 3AX, S Glam, Wales
[2] ALK, Horsholm, Denmark
基金
英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词
QUALITY-OF-LIFE; RHINITIS; CONJUNCTIVITIS; PREVALENCE; SEVERITY; TABLETS; BURDEN; MODELS; IMPACT; COST;
D O I
10.1186/1477-7525-12-99
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Grass allergen immunotherapy (AIT) reduces symptom severity in seasonal allergic rhinoconjunctivitis (ARC) but its impact on general health-related utility has not been characterised for the purposes of economic evaluation. The aim of this study was to model the preferred measure of utility, EQ-5D index, from symptom severity and estimate incremental quality adjusted life years (QALYs) associated with SQ-standardised grass immunotherapy tablet (GRAZAX (R), 75,000 SQ-T/2,800 BAU, ALK, Denmark). Methods: Data were analysed from five consecutive pollen seasons in a randomised placebo controlled trial of GRAZAX (R). Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and medication scores (DSS & DMS respectively). In turn, daily EQ-5D index was estimated from ARC symptoms and medication use. Results: DSS and DMS were the principal predictors of 'perfect' health (EQ-5D = 1.000; binomial) and 'imperfect' health (EQ-5D < 1.000; Gaussian). Each unit increase in DSS and DMS reduced the odds of 'perfect' health (EQ-5D = 1.000) by 27% and 16% respectively, and reduced 'imperfect' health by 0.17 and 0.13, respectively. Gender remained the only other significant main fixed effect (Male odds ratio [OR] = 1.82). Incremental estimated EQ-5D index utility for GRAZAX (R) was observed from day -30 to day +70 of the pooled pollen season; mean daily utility for GRAZAX (R) = 0.938 units (95% CI 0.932-0.943) vs. 0.914 (0.907-0.921) for placebo, an incremental difference of 0.0238 (p < 0.001). This translates into an incremental 0.0324 Quality Adjusted Life Years over the five year study period. Conclusions: ARC symptoms and medication use are the main predictors of EQ-5D index. The incremental QALYs observed for GRAZAX (R) may not fully describe the health benefits of this treatment, suggesting that economic modelling may be conservative.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Health-Related Utility of EQ-5D in Korean Adults With Chronic Urticaria: Mapping From Urticaria Outcome Measures
    Lee, Min-Sang
    Yoon, Jiwon
    Kim, Jiwoong
    Shin, Yoo Seob
    Park, Hae-Sim
    Lee, Hyun-Young
    Ye, Young-Min
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2020, 12 (04) : 599 - 607
  • [2] Estimation of Health-Related Quality of Life in the Presence of Missing Values in EQ-5D
    Atif, Muhammad
    Zaman, Qamruz
    Shafiq, Muhammad
    Abdel-Salam, Abdel-Salam G.
    MATHEMATICAL PROBLEMS IN ENGINEERING, 2021, 2021
  • [3] Health-Related Quality of Life Based on EQ-5D Utility Score in Patients With Tuberculosis: A Systematic Review
    Park, Hae-Young
    Cheon, Hyo-Bin
    Choi, Sun Ha
    Kwon, Jin-Won
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [4] Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany
    Verheggen, Bram G.
    Westerhout, Kirsten Y.
    Schreder, Carl H.
    Augustin, Matthias
    CLINICAL AND TRANSLATIONAL ALLERGY, 2015, 5
  • [5] Validation of EQ-5D and 15D in the assessment of health-related quality of life in chronic pain
    Vartiainen, Pekka
    Mantyselka, Pekka
    Heiskanen, Tarja
    Hagelberg, Nora
    Mustola, Seppo
    Forssell, Heli
    Kautiainen, Hannu
    Kalso, Eija
    PAIN, 2017, 158 (08) : 1577 - 1585
  • [6] Health-related quality of life in diabetes: The associations of complications with EQ-5D scores
    Solli, Oddvar
    Stavem, Knut
    Kristiansen, I. S.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2010, 8
  • [7] The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers
    Orgeta, Vasiliki
    Edwards, Rhiannon Tudor
    Hounsome, Barry
    Orrell, Martin
    Woods, Bob
    QUALITY OF LIFE RESEARCH, 2015, 24 (02) : 315 - 324
  • [8] Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and health utilities index
    Pickard, AS
    Johnson, JA
    Feeny, DH
    Shuaib, A
    Carriere, KC
    Nasser, AM
    STROKE, 2004, 35 (02) : 607 - 612
  • [9] Measuring health-related quality of life in Kashin–Beck disease using EQ-5D
    Umer Farooq
    Xiong Guo
    Ling-Hsiang Chuang
    Hua Fang
    Guihua Zhuang
    Chuantao Xia
    Quality of Life Research, 2011, 20 : 425 - 429
  • [10] Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D
    Fogarty, Emer
    Walsh, Cathal
    Adams, Roisin
    McGuigan, Christopher
    Barry, Michael
    Tubridy, Niall
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (09) : 1190 - 1196